Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore

VESALIUS-CV

Evolocumab In Patients Without Significant Atherosclerosis: Results From VESALIUS-CV

Presented by Nicholas Marston — TIMI Study Group

Subspecialty: Lipid / Prevention

Published in NEJM

Key Result

PCSK9 inhibitor evaluated in primary prevention with 13K patients

Part of ESC Congress 2026 — European Society of Cardiology Annual Congress, Munich

View this trial on Synapse: synapsesocial.com/esc/trials/vesalius-cv

View all ESC 2026 trialsResults in
4

VESALIUS-CV

Evolocumab In Patients Without Significant Atherosclerosis: Results From VESALIUS-CV

105-09Lipid / PreventionNEJMTrending
Impact Score
196

Key Result

  • PCSK9 inhibitor evaluated in primary prevention with 13K patients

Discussion (0)

Be the first to discuss VESALIUS-CV. Share your insights or questions.